Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 10, 2015, Pages 424.e17-424.e23

  De Luca, Stefano ^a   Passera, Roberto ^b   Fiori, Cristian ^a   Bollito, Enrico ^a   Cappia, Susanna ^a   Mario Scarpa, Roberto ^a   Sottile, Antonino ^c   Franco Randone, Donato ^d   Porpiglia, Francesco ^a  

^a San Luigi Gonzaga Hospital and University of Torino   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c CANDIOLO CANCER INSTITUTE   (Italy)

^d GRADENIGO HOSPITAL   (Italy)

Author keywords

Differential diagnosis; Percentage of free prostate specific antigen; Prostate cancer; Prostate cancer antigen 3 gene; Prostate health index; Prostate specific antigen; Prostatitis

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; CHRONIC PROSTATITIS; CLINICAL ASSESSMENT; COHORT ANALYSIS; DIGITAL RECTAL EXAMINATION; FALSE NEGATIVE RESULT; HIGH GRADE PROSTATE INTRAEPITHELIAL NEOPLASIA; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PARENCHYMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER GENE 3 SCORE; PROSTATE HEALTH INDEX; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATITIS; REPEAT PROCEDURE; VERY ELDERLY;

EID: 84942195112     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.05.032     Document Type: Article

References (31)

1. Nadler R.B., Humphrey P.A., Smith D.S., Catalona W.J., Ratliff T.L. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate-specific antigen levels. J Urol 1995, 154:407-413.
2. Sfanos K.S., De Marzo A.M. Prostate cancer and inflammation: the evidence. Histopathology 2012, 60:199-215.
3. Okada K., Kojima M., Naya Y., Kamoi K., Yokoyama K., Takamatsu T., et al. Correlation of histological inflammation in needle biopsy specimens with serum prostate-specific antigen levels in men with negative biopsy for prostate cancer. Urology 2000, 55:892-898.
4. Wolters T., Roobol M.J., Schröder F.H., van der Kwast T.H., Roemeling S., van der Cruijsen-Koeter I.W., et al. Can non-malignant biopsy features identify men at increased risk of biopsy-detectable prostate cancer at re-screening after four years?. BJU Int 2008, 101:283-288.
5. Karakiewicz P.I., Benayoun S., Bégin L.R., Duclos A., Valiquette L., McCormack M., et al. Chronic inflammation is negatively associated with prostate cancer and high-grade prostatic intraepithelial neoplasia on needle biopsy. Int J Clin Pract 2007, 61:425-430.
6. De Luca S., Passera R., Bollito E., Manfredi M., Scarpa R.M., Sottile A., et al. Comparison of prostate cancer gene 3 score, prostate health index and percentage free prostate-specific antigen for differentiating histological inflammation from prostate cancer and other non-neoplastic alterations of the prostate at initial biopsy. Anticancer Res 2014, 34:7159-7165.
7. MacLennan G.T., Eisenberg R., Fleshman R.L., Taylor J.M., Fu P., Resnick M.I., et al. The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J Urol 2006, 176:1012-1016.
8. Terakawa T., Miyake H., Kanomata N., Kumano M., Takenaka A., Fujisawao M. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50ng/ml. Urology 2008, 72:1194-1197.
9. Greene K.L., Albertsen P.C., Babaian R.J., Carter H.B., Gann P.H., Han M., et al. Prostate-specific antigen best practice statement: 2009 update. J Urol 2009, 182:2232-2241.
10. Thakur V., Talwar M., Singh P.P. Low free to total PSA ratio is not a good discriminator of chronic prostatitis and prostate cancer: an Indian experience. Indian J Cancer 2014, 51:335-337.
11. Hessels D., Klein Gunnewiek J.M., van Oort I., Karthaus H.F., van Leenders G.J., van Balken B., et al. DD3 (PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003, 44:8-15.
12. Groskopf J., Aubin S.M., Deras I.L., Blase A., Bodrug S., Clark C., et al. Aptima PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006, 52:1089-1095.
13. Deras I.L., Aubin S.M., Blase A., Day J.R., Koo S., Partin A.W., et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008, 179:1587-1592.
14. Vlaeminck-Guillem V., Bandel M., Cottancin M., Rodriguez-Lafrasse C., Bohbot J.M., Sednaoui P. Chronic prostatitis does not influence urinary PCA3 score. Prostate 2012, 72:549-554.
15. Lazzeri M., Abrate A., Lughezzani G., Gadda G.M., Freschi M., Mistretta F., et al. Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and Prostate Health Index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination. Urology 2014, 83:606-612.
16. Joseph D.A., Thompson T., Saraiya M., Werny D.M. Association between glomerular filtration rate, free, total, and percent free prostate-specific antigen. Urology 2010, 76:1042-1046.
17. Agenzia Italiana del Farmaco. Linee guida per la classificazione e la conduzione degli studi osservazionali sui farmaci. Roma 20.03.2008.
18. Neal D.E., Clejan S., Sarma D., Moon T.D. Prostate specific antigen and prostatitis. I. Effect of prostatitis on serum PSA in the human and nonhuman primate. Prostate 1992, 20:105-111.
19. Lin Y.K., Gettle L., Raman J.D. Variable prostate-specific antigen management patterns by nonurologist providers at a tertiary care medical center. Urology 2011, 78:244-248.
20. Sfanos K.S., Isaacs W.B., De Marzo A.M. Infections and inflammation in prostate cancer. Am J Clin Exp Urol 2013, 1:3-11.
21. Fujita K., Hosomi M., Tanigawa G., Okumi M., Fushimi H., Yamaguchi S. Prostatic inflammation detected in initial biopsy specimens and urinary pyuria are predictors of negative repeat prostate biopsy. J Urol 2011, 185:1722-1727.
22. Nickel J.C., True L.D., Krieger J.N., Berger R.E., Boag A.H., Young I.D. Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int 2001, 87:797-805.
23. Delongchamps N., de la Roza G., Chandan V., Jones R., Sunheimer R., Threatte G., et al. Evaluation of prostatitis in autopsied prostates-is chronic inflammation more associated with benign prostatic hyperplasia or cancer?. J Urol 2008, 179:1736-1740.
24. De Marzo A.M., Platz E.A., Sutcliffe S., Xu J., Gronberg H., Drake C.G., et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007, 7:256-269.
25. Habermacher G.M., Chason J.T., Schaeffer A.J. Prostatitis/chronic pelvic pain syndrome. Annu Rev Med 2006, 57:195-206.
26. Scardino P.T. The responsible use of antibiotics for an elevated PSA level. Nat Clin Pract Urol 2007, 4:1.
27. Jung K., Meyer A., Lein M., Rudolph B., Schnorr D., Loenings A. Ratio of free to total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate. J Urol 1998, 159:1595-1598.
28. Haese A., de la Taille A., van Poppel H., Marberger M., Stenzl A., Mulders P.F., et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008, 54:1081-1088.
29. Auprich M., Haese A., Walz J., Pummer K., de la Taille A., Graefen M., et al. External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. Eur Urol 2010, 58:727-732.
30. Lazzeri M., Haese A., de la Taille A., Palou Redorta J., McNicholas T., Lughezzani G., et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10ng/ml: a multicentric European study. Eur Urol 2013, 63:986-994.
31. De Luca S., Passera R., Milillo A., Coda R., Randone D.F. Histological chronic prostatitis and high-grade prostate intra-epithelial neoplasia do not influence urinary prostate cancer gene 3 score. BJU Int 2012, 110:e778-e782.